ALFA Finder| Management target | Revenue FY27 |
|---|
| Margins | PAT turnaround at Ratna Lifescience from loss to ₹7.8 Cr. |
|---|---|
| Order book | IVD section received ₹50 Cr government order in 2021-22. |
| Demand visibility | Strong targeting of regulated and semi-regulated markets. |
| Management confidence | High |
Growth
Ratna Lifescience revenue grew from ₹0.02 Cr in FY23 to ₹35.30 Cr in FY26; PAT rose to ₹7.8 Cr.
Outlook
Targeting minimum ₹100 Cr export turnover for FY27; planned $20M FCCB allotment; new Hyderabad unit development.
Risks
Expansion into regulated markets like USA/Europe involves high regulatory compliance and competition from Chinese API imports.
Investor Presentation filed with BSE, BSE: 543828. Summary written with AI assistance from the document.
Sudarshan Pharma Industries Ltd: key numbers
- Share price
- ₹33.60
- Market cap
- ₹808.6 Cr
- Revenue (annual)
- ₹703.1 Cr
- Net profit (annual)
- ₹23.30 Cr
- P/E (TTM)
- 34.7×Sector 35.5×
- Promoter holding
- 57.81%-1.12% QoQ
- FII holding
- 21.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudarshan Pharma Industries Ltd
All →Sudarshan Pharma Industries Management Change
Sudarshan Pharma's Company Secretary and Compliance Officer, Nirav Shah, resigned effective November 9, 2026. The resignation was for better prospects, with no other reason cited.
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
Sudarshan Pharma Industries Q2 FY27 Results: Net Profit ₹8.1 Cr, Up 92.9% YoY
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹217 Cr (+28.5% YoY) and net profit of ₹8.1 Cr (+92.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹8.1 Cr · +92.9% YoY
Sudarshan Pharma Industries Board Meeting Date
Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.
Sudarshan Pharma Industries SME to Main Board Migration
Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.